Dr. Robin Downing podcast spotlights practical OA pain strategies

Clinician’s Brief has released a sponsored podcast featuring Dr. Robin Downing on practical osteoarthritis pain management, framing OA as a condition that requires earlier recognition, broader treatment planning, and better communication with pet parents, not just a prescription at the point mobility declines. The episode, published as “Osteoarthritis Pain: Beyond NSAIDs with Dr. Robin Downing,” is backed by PRN Pharmacal and positions Downing’s message around more complete pain-control strategies and quality-of-life discussions in practice. (cliniciansbrief.com)

That message fits squarely within the direction of current veterinary guidance. The 2022 AAHA Pain Management Guidelines describe chronic musculoskeletal pain, especially osteoarthritis, as a major focus area and recommend proactive, multimodal management with regular reevaluation. The guidelines also highlight the use of validated client-facing assessment tools, including the Canine Brief Pain Inventory, LOAD, and SNoRE, reflecting a broader shift toward longitudinal monitoring rather than relying only on in-clinic impressions or late-stage lameness. (aaha.org)

Additional Clinician’s Brief podcast coverage underscores how broad that multimodal approach has become in real-world practice. In a Hills-sponsored episode on mobility and joint health, sports medicine and rehab specialist Dr. Matt Brunke argued that management needs to extend beyond medications and supplements to include rehabilitation, activity planning, and weight control. He also called attention to cats, noting that many indoor cats are overweight, can develop primary osteoarthritis as they age, and often show mobility decline in subtle ways that are easy to overlook without asking owners about jumping, stair use, and other daily behaviors. That framing complements Downing’s emphasis on earlier recognition and more functional conversations with pet parents. (Clinician’s Brief, “Practical Strategies for Mobility & Joint Health With Dr. Brunke”)

The broader OA treatment environment has also changed since earlier guideline cycles. Anti-nerve growth factor monoclonal antibodies have become a major part of the conversation, particularly bedinvetmab for dogs. In a 2025 randomized clinical trial published in Frontiers in Veterinary Science, bedinvetmab and meloxicam both significantly reduced osteoarthritis pain scores over 56 days, with no statistically significant efficacy difference between groups. The bedinvetmab arm had fewer reported adverse events, though the authors noted the short study duration limits long-term safety conclusions. (frontiersin.org)

At the same time, pharmacovigilance has become more visible in day-to-day practice. FDA’s February 18, 2025, safety-related labeling changes for Librela added a post-approval experience subsection, a new information section for dog owners, and instructions for veterinarians to review a client information sheet before administration. FDA’s related Dear Veterinarian letter said the agency had evaluated reported adverse events in dogs treated with Librela and asked clinicians to include details such as full medical history, number of prior doses, and vial lot number when reporting cases. (fda.gov)

Industry and expert reaction has reflected both enthusiasm for expanded OA options and caution about how they’re used. Zoetis highlighted the 2025 comparator study as support for guidelines that place both NSAIDs and Librela among first-line options for canine OA pain. Meanwhile, recent commentary in the literature has pushed for closer scrutiny of musculoskeletal adverse-event reports and for the same rigorous post-market evaluation expected in human biologics. Taken together, that suggests the field is not moving away from newer OA therapies, but it is asking harder questions about selection, monitoring, and informed consent. (news.zoetis.com)

Why it matters: For veterinary teams, the practical takeaway is that OA pain management is now as much a systems issue as a prescribing issue. Success depends on recognizing pain earlier, choosing the right mix of interventions, documenting response with repeatable tools, and preparing pet parents for ongoing reassessment. That’s especially relevant as practices weigh NSAIDs, anti-NGF products, rehabilitation, body-weight management, environmental modification, and adjunctive support in different combinations. The Downing podcast appears to speak directly to that reality, and Brunke’s mobility-focused discussion reinforces it: clinicians need plans that are clinically flexible, attentive to subtle signs in cats as well as dogs, understandable to pet parents, and sustainable over time. (cliniciansbrief.com)

What to watch: The next phase in OA management will likely center on how practices operationalize monitoring, rehab and weight-management support, and communication around newer therapies, especially as more post-approval safety data, comparative studies, and consensus recommendations emerge over 2026. (fda.gov)